List of Vitrakvi drug patents

Vitrakvi is owned by Bayer Hlthcare.

Vitrakvi contains Larotrectinib Sulfate.

Vitrakvi has a total of 13 drug patents out of which 0 drug patents have expired.

Vitrakvi was authorised for market use on 26 November, 2018.

Vitrakvi is available in capsule;oral dosage forms.

Vitrakvi can be used as method of treating cancerous solid tumors, method of treating lung cancer, undifferentiated sarcoma, or colorectal cancer that exhibits an ntrk gene fusion, method of treating solid tumors that exhibit an ntrk gene fusion after surgical resection, method of treating neuroblastoma, glioma, thyroid, and breast cancer solid tumors that exhibit an ntrk gene fusion, method of treating solid tumors that exhibit an ntrk gene fusion in a pediatric patient, method of treating solid tumors that exhibit an ntrk gene fusion.

Drug patent challenges can be filed against Vitrakvi from November, 2022.

The generics of Vitrakvi are possible to be released after 15 August, 2036.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9127013 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Oct, 2029

(6 years from now)

US8513263 BAYER HLTHCARE Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
Dec, 2029

(6 years from now)

US10172861 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(12 years from now)

US10799505 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Aug, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10047097 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Oct, 2029

(6 years from now)

US9447104 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
Oct, 2029

(6 years from now)

US8865698 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
Oct, 2029

(6 years from now)

US10005783 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Oct, 2029

(6 years from now)

US9676783 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
Oct, 2029

(6 years from now)

US10774085 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
Oct, 2029

(6 years from now)

US10285993 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(12 years from now)

US9782414 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(12 years from now)

US10813936 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 26, 2025
New Chemical Entity Exclusivity (NCE) Nov 26, 2023

Drugs and Companies using LAROTRECTINIB SULFATE ingredient

NCE-1 date: November, 2022

Market Authorisation Date: 26 November, 2018

Treatment: Method of treating solid tumors that exhibit an ntrk gene fusion after surgical resection; Method of treating solid tumors that exhibit an ntrk gene fusion; Method of treating cancerous solid tumors; Method of treating neuroblastoma, glioma, thyroid, and breast cancer solid tumors that exhibit an ntrk gene fusion; Method of treating solid tumors that exhibit an ntrk gene fusion in a pediatric patient; Method of treating lung cancer, undifferentiated sarcoma, or colorectal cancer that exhibits an ntrk gene fusion

Dosage: CAPSULE;ORAL

More Information on Dosage

Vitrakvi is owned by Bayer Healthcare.

Vitrakvi contains Larotrectinib Sulfate.

Vitrakvi has a total of 14 drug patents out of which 0 drug patents have expired.

Vitrakvi was authorised for market use on 26 November, 2018.

Vitrakvi is available in solution;oral dosage forms.

Vitrakvi can be used as method of treating cancerous solid tumors, method of treating solid tumors that exhibit an ntrk gene fusion after surgical resection, method of treating neuroblastoma, glioma, thyroid, and breast cancer solid tumors that exhibit an ntrk gene fusion, method of treating solid tumors that exhibit an ntrk fusion gene in a pediatric patient, method of treating cmn, ifs, hgg, dipgs, ptc, soft tissue sarcoma, and spindle cell sarcoma solid tumors exhibiting an ntrk gene fusion in a pediatric patient with an oral solution, method of treating solid tumors that exhibit an ntrk gene fusion.

Drug patent challenges can be filed against Vitrakvi from November, 2022.

The generics of Vitrakvi are possible to be released after 04 April, 2037.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9127013 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Oct, 2029

(6 years from now)

US8513263 BAYER HEALTHCARE Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
Dec, 2029

(6 years from now)

US10172861 BAYER HEALTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(12 years from now)

US10799505 BAYER HEALTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Aug, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10047097 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Oct, 2029

(6 years from now)

US8865698 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
Oct, 2029

(6 years from now)

US10005783 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Oct, 2029

(6 years from now)

US9447104 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
Oct, 2029

(6 years from now)

US9676783 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
Oct, 2029

(6 years from now)

US10774085 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
Oct, 2029

(6 years from now)

US9782414 BAYER HEALTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(12 years from now)

US10045991 BAYER HEALTHCARE Methods of treating pediatric cancers
Apr, 2037

(14 years from now)

US10668072 BAYER HEALTHCARE Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
Apr, 2037

(14 years from now)

US10137127 BAYER HEALTHCARE Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
Apr, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 26, 2025
New Chemical Entity Exclusivity (NCE) Nov 26, 2023

Drugs and Companies using LAROTRECTINIB SULFATE ingredient

NCE-1 date: November, 2022

Market Authorisation Date: 26 November, 2018

Treatment: Method of treating solid tumors that exhibit an ntrk gene fusion after surgical resection; Method of treating cancerous solid tumors; Method of treating neuroblastoma, glioma, thyroid, and breast cancer solid tumors that exhibit an ntrk gene fusion; Method of treating solid tumors that exhibit an ntrk gene fusion; Method of treating solid tumors that exhibit an ntrk fusion gene in a pediatric patient; Method of treating cmn, ifs, hgg, dipgs, ptc, soft tissue sarcoma, and spindle cell sarcoma solid tumors exhibiting an ntrk gene fusion in a pediatric patient with an oral solution

Dosage: SOLUTION;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic